
Ipsen has reported positive topline results from its phase 3 BEOND clinical programme evaluating Dysport (abobotulinumtoxinA) for the prevention of …

Ipsen has secured an expansion in the UK to the existing label for Dysport (lemborexant), with the Medicines and Healthcare …

